- Home
- VRDN
as 11-01-2025 4:26am EST
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 1.6B | IPO Year: | N/A |
| Target Price: | $36.78 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.56 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.90 - $27.20 | Next Earning Date: | 11-13-2025 |
| Revenue: | $305,000 | Revenue Growth: | 5.90% |
| Revenue Growth (this year): | -49.68% | Revenue Growth (next year): | 34044.63% |
Stock Insider Trading Activity of Viridian Therapeutics Inc. (VRDN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | VRDN | Director, 10% Owner | Oct 23 '25 | Buy | $22.00 | 454,545 | $9,999,990.00 | 3,914,458 |
Latest Viridian Therapeutics Inc. News
VRDN Breaking Stock News: Dive into VRDN Ticker-Specific Updates for Smart Investing
Barrons.com
2 days ago
Astria, Viridian Therapeutics, and More Stocks See Action From Activist Investors
24/7 Wall St.
6 days ago
Insiders Are Buying These 3 Stocks Hand Over Fist
MT Newswires
6 days ago
Wedbush Raises Price Target on Viridian Therapeutics to $42 From $40, Keeps Outperform Rating
Business Wire
a month ago
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
5 months ago
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
5 months ago
Viridian Therapeutics to Participate in Upcoming June Investor Conferences
Business Wire
5 months ago
Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)
Business Wire
6 months ago
Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)
Compare VRDN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VRDN Viridian Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.